Covid-19 roundup: Novavax may not go to FDA until June at earliest — report; Bourla pushes back against IP waiver in public letter

Nicole DeFeudis

Editor

Max Gelman

Senior Editor

Jason Mast

Editor

Public health officials hoping to rollout Novavax’s Covid-19 vaccine will have to wait a bit longer. The company will not file for authorization with the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: Novavax may not go to FDA until June at earliest — report; Bourla pushes back against IP waiver in public letter

Nicole DeFeudis

Editor

Max Gelman

Senior Editor

Jason Mast

Editor

Sign up to read this article for free.

Trump announces picks for FDA, CDC; Novartis seeks bolt-on deals, raises guidance; RFK Jr., Elon Musk may find ...

For CDC, Trump picks Dave Weldon, a former congressman who pushed for vaccine injury claims

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Sanofi introduces new 340B payment model — report

Are programs with compounded GLP-1s safe for your population?

Covid-19 roundup: No­vavax may not go to FDA un­til June at ear­li­est — re­port; Bourla push­es back against IP waiv­er in pub­lic let­ter

Editor

Senior Editor

Editor

Sign up to read this article for free.

Covid-19 roundup: Novavax may not go to FDA until June at earliest — report; Bourla pushes back against IP waiver in public letter